Results 121 to 130 of about 1,772,527 (156)

Histone deacetylase inhibitors as venetoclax‐sensitising partners in acute myeloid leukaemia: Mechanisms, pharmacology and translational perspectives

open access: yesBritish Journal of Pharmacology, Volume 183, Issue 21, Page 6261-6290, November 2026.
Abstract Venetoclax combined with hypomethylating agents has improved treatment for older or unfit patients with acute myeloid leukaemia (AML), but resistance and relapse remain common. This review analyses the rationale for combining venetoclax with inhibitors of histone deacetylase (HDAC).
Jaebok Lee, Marc Diederich
wiley   +1 more source

KRAS Mutations Predict Inferior Post‐Remission Outcomes in Newly Diagnosed Acute Myeloid Leukemia With MAPK Pathway Mutations

open access: yesEuropean Journal of Haematology, Volume 117, Issue 5, Page 1318-1326, November 2026.
ABSTRACT Somatic mutations in the MAPK signaling pathway are frequently identified at AML diagnosis; however, their impact on treatment resistance and long‐term survival remains unclear. We conducted a retrospective study of patients with newly diagnosed MAPK‐mutated AML seen at the University of Iowa Health Care.
Kensuke Takaoka   +6 more
wiley   +1 more source

Dose‐Adjusted Treatment With 7‐Day Venetoclax Plus Azacitidine or Decitabine in Patients With Acute Myeloid Leukaemia

open access: yesEuropean Journal of Haematology, Volume 117, Issue 5, Page 1358-1368, November 2026.
ABSTRACT Acute myeloid leukaemia (AML) in older or unfit patients is commonly treated with hypomethylating agents (HMA) plus venetoclax (VEN), but prolonged VEN exposure often causes substantial haematological toxicity. We retrospectively analysed 61 elderly AML patients treated with HMA + VEN for 7 (7d), 14 (14d) or > 14 days (> 14d) per cycle.
Laurenz Steiner   +12 more
wiley   +1 more source

P572: REAL-WORLD MANAGEMENT AND OUTCOMES FOR NEWLY DIAGNOSED AML PATIENTS INITIATING VENETOCLAX AND HYPOMETHYLATING AGENTS IN US COMMUNITY PRACTICE

open access: yesHemaSphere, 2023
Yuexi Wang   +7 more
doaj   +1 more source

Sustained disease remission with reduced‐intensity allogeneic hematopoietic cell transplant for VEXAS syndrome

open access: yes
HemaSphere, Volume 10, Issue 11, November 2026.
Bhavisha A. Patel   +34 more
wiley   +1 more source

PB1861: EFFICACY AND TOXICITY OF VENETOCLAX PLUS HYPOMETHYLATING AGENTS IN THE REAL LIFE OF ACUTE MYELOID LEUKEMIA

open access: yesHemaSphere, 2023
Gianluca Martini   +8 more
doaj   +1 more source

Therapeutic Options in Myelodysplastic Syndromes Following Hypomethylating Agent Failure

open access: yesJournal of Scientific Innovation in Medicine, 2020
Abigail Belasen, Shyamala Navada
doaj   +1 more source

Increased Expression of CD70 in Relapsed Acute Myeloid Leukemia After Hypomethylating Agents

open access: yes
Acute myeloid leukemia (AML) is the most common acute leukemia in adults. While induction chemotherapy leads to remission in most patients, a significant number will experience relapse.
Panowski, Siler   +25 more
core   +1 more source

The role of the adenosinergic pathway in resistance to hypomethylating agents in patients with high‐risk myelodysplastic syndromes

open access: yes
British Journal of Haematology, Volume 209, Issue 5, Page 2335-2340, November 2026.
George Vrachiolias   +15 more
wiley   +1 more source

P1738: A SEER-MEDICARE ANALYSIS OF THE ECONOMIC BURDEN AMONG ELDERLY PATIENTS WITH ACUTE MYELOID LEUKEMIA TREATED WITH HYPOMETHYLATING AGENTS

open access: yesHemaSphere, 2022
A. McBride   +7 more
doaj   +1 more source

Home - About - Disclaimer - Privacy